ARFGEF1

Across TCGA pan-cancer cohorts, ARFGEF1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ARFGEF1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARFGEF1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ARFGEF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and UCS show a favorable association.

UCEC, STAD, and DLBC are the cancer types where ARFGEF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.896	0.300	.009	24	view →
STAD	OS	Median	All	0.184	0.730	.002	18	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.223	0.527	.027	12	view →
LUAD	OS	Median	III,IV	0.146	0.690	<.001	12	view →
READ	DFS	Median	All	0.162	0.720	.019	6	view →
SCLC	OS	Median	II,III,IV	0.203	0.830	.011	6	view →
LUSC	DFS	Median	All	0.303	0.719	.005	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →
UCS	DFS	Median	All	1.000	0.224	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ARFGEF1–UCEC (DFS)

Open the UCEC breakdown →